12,261 trials (keyword fallback)
Non-Hodgkin's Lymphoma · Diffuse Large Cell Lymphoma · Mantle Cell Lymphoma
Primary: Event-free Survival (EFS) — 83 percentage of not experiencing EFS event
B-cell Lymphoma · Indolent B-cell Lymphoma
Primary: Determine Complete Response Rate (CRR) of Increased Dose Rituximab in Indolent B-cell Lymphomas — 21 Participants
Hodgkin's Disease · Leukemia · Myelodysplastic Syndrome
Primary: Safety of Rituximab Prophylaxis — 23 participants
Lymphoma, Large-Cell, Anaplastic · Enteropathy-Associated T-Cell Lymphoma · Lymphoma, Large B-Cell, Diffuse
Primary: Maximum Tolerated Dose of Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) in Participants With Advanced…
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) With Response as Assessed by the Investigator — 31 participants
Multiple Sclerosis
Primary: Number of Patients With a Return of Disease Activity After the Third Month Post-first-infusion — 3; 6 Participants
Cutaneous T Cell Lymphoma · Peripheral T Cell Lymphoma
Primary: Number of Participants With a Response — 17; 28; 8; 5 participants
Lymphomas · Solid Tumors · NSCLC
Primary: Phase 2: Response Rate of This Combination in Participants With Colon Cancer, Non-small Cell Lung Cancer (NSCLC), and Granulosa Cell Ovarian Cancer — 0; 0; 0; 1…
Lymphoma · Hodgkin Disease · Lymphoma, Non-Hodgkin
Primary: 68Ga-DOTANOC Uptake in Lymphomas With PET/CT — 3.1 Standardized Uptake Value
Lymphoma, T-Cell · Lymphoma, Extranodal NK-T-Cell
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab — 30 mg
Adult Grade III Lymphomatoid Granulomatosis · B-cell Chronic Lymphocytic Leukemia · Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Primary: Dose-limiting Toxicity (Phase I) — 0; 0; 2 Participants
Recurrent B-Cell Non-Hodgkin Lymphoma · Recurrent Chronic Lymphocytic Leukemia · Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Primary: Proportion of Patients Who Achieve a Confirmed Response — 0.0800; 0; 0 proportion of responders
CD19+ Diffuse Large B-cell Lymphomas · Follicular Lymphomas · Mantle Cell Lymphomas
Primary: Dose-limiting Toxicity — 8.33 percentage of subjects
Neoplasms · Lymphomas
Primary: Dose Limiting Toxicity (DLTs) — 0; 0; 0; 0 Toxicities
T Cell Lymphoma
Primary: Overall Response Rate — 5 participants